Fibroblast Growth Factor Binding Protein 3 (FGFBP3) therapy to treat Diabetes and Obesity

Summary of the technology

- Potential treatment for diabetes, obesity, and related metabolic diseases.
- The protein FGFBP3 enhances FGF binding affinity, causing long-term reduction in hyperglycemia and gluconeogenesis in affected patients.
- Safer alternative to current diabetes treatments, as it does not cause life-threatening hypoglycemia or promote mitogenic effects, and normalizes blood sugar levels for over 24 hours after a single dose.

Georgetown University

OVERVIEW

Georgetown researchers demonstrate that a single injection of the protein FGFBP3 alone is enough to restore the body’s ability to regulate insulin and blood sugar levels to a healthy range for more than 24 hours. Our researchers show that FGFBP3 enhances the binding affinity of Fibroblast Growth Factors 15/19 (FGFs15/19) to their preferential receptors, leading to a normalization of hyperglycemia, and reducing G6PC expression and gluconeogenesis.

BACKGROUND

Metabolic syndrome, if left unmanaged, can lead to stroke, type 2 diabetes, heart disease, non-alcoholic fatty liver disease, and even death. This syndrome is characterized by an unfavorable dysregulation of fat and glucose metabolism. Therefore, treatments with the ability to promote favorable metabolic signaling could be used to improve the health of patients with metabolic syndrome and manage associated pathologies.

Benefit

Use of FGFBP3 for the treatment of diabetes, obesity, and related metabolic diseases

Market Application

  • A novel treatment method for diabetes, obesity, and related metabolic diseases
  • Unlike the side effects of current diabetes treatments, this approach with FGFBP3 leads to:
    • ​Increased insulin sensitivity
    • Restoration of normal blood sugar levels without causing life-threatening hypoglycemia
    • Normalized blood sugar levels lasting for over 24 hours after a single dose
    • Safer treatments, as the proposed therapeutic does not promote mitogenic effects as exogenous FGF19/21 injections do
  • Biologic therapies are known for their higher probability of regulatory success compared to small molecules

Publications

  • US patent No. 14/853,482
  • Fibroblast Growth Factor Binding Protein 3 (FGFBP3) impacts carbohydrate and lipid metabolism (DOI: https://doi.org/10.1101/2021.07.28.454226) (link: https://www.biorxiv.org/content/10.1101/2021.07.28.454226v2)

Related Keywords

  • Biological Sciences
  • Medicine, Human Health
  • Therapeutic
  • metabolic disorders
  • obesity treatment
  • therapy
  • lipid metabolism
  • diabetes treatment

About Georgetown University

Our mission is to advance GU’s innovations through strategic alliances and new venture creation, to facilitate the translation of research breakthroughs into tangible solutions, and to cultivate a dynamic and inclusive environment for entrepreneurship. We advance this mission in support of the GU community and for the benefit of society.

Georgetown University

Never miss an update from Georgetown University

Create your free account to connect with Georgetown University and thousands of other innovative organizations and professionals worldwide

Georgetown University

Send a request for information
to Georgetown University

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.

Help

Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support